Inotiv, Inc. (NOTV)
USD 1.55
(3.33%)
USD 1.55
(3.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -81.46 Million USD | -196.79% |
| 2022 | -27.44 Million USD | -1889.24% |
| 2021 | 1.53 Million USD | 150.08% |
| 2020 | -3.06 Million USD | -1901.96% |
| 2019 | -153 Thousand USD | -1192.86% |
| 2018 | 14 Thousand USD | -98.9% |
| 2017 | 1.27 Million USD | 142.04% |
| 2016 | -3.04 Million USD | -434.43% |
| 2015 | 909 Thousand USD | 172.16% |
| 2014 | 334 Thousand USD | -59.76% |
| 2013 | 830 Thousand USD | 114.6% |
| 2012 | -5.68 Million USD | -541.8% |
| 2011 | 1.28 Million USD | 164.45% |
| 2010 | -1.99 Million USD | 56.59% |
| 2009 | -4.6 Million USD | -264.64% |
| 2008 | 2.79 Million USD | 16.9% |
| 2007 | 2.39 Million USD | 169.83% |
| 2006 | -3.42 Million USD | -371.63% |
| 2005 | 1.26 Million USD | 396.06% |
| 2004 | 254 Thousand USD | -68.25% |
| 2003 | 800 Thousand USD | -50.82% |
| 2002 | 1.62 Million USD | -53.39% |
| 2001 | 3.49 Million USD | 392.74% |
| 2000 | -1.19 Million USD | -232.48% |
| 1999 | 900 Thousand USD | 28.57% |
| 1998 | 700 Thousand USD | -36.36% |
| 1997 | 1.1 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -40.41 Million USD | -464.89% |
| 2024 Q3 | -17.29 Million USD | 48.65% |
| 2024 Q1 | -7.15 Million USD | -390.81% |
| 2023 Q2 | -1.58 Million USD | 93.47% |
| 2023 Q3 | 8.78 Million USD | 655.89% |
| 2023 Q4 | 2.46 Million USD | -71.99% |
| 2023 Q1 | -24.21 Million USD | -190.72% |
| 2023 FY | -81.46 Million USD | -196.79% |
| 2022 Q3 | 4.78 Million USD | -39.16% |
| 2022 Q1 | -33.64 Million USD | -887.12% |
| 2022 Q2 | 7.86 Million USD | 123.39% |
| 2022 FY | -27.44 Million USD | -1889.24% |
| 2022 Q4 | -8.32 Million USD | -273.97% |
| 2021 Q1 | 14 Thousand USD | 101.02% |
| 2021 Q3 | -1.7 Million USD | -226.87% |
| 2021 FY | 1.53 Million USD | 150.08% |
| 2021 Q4 | -3.4 Million USD | -100.12% |
| 2021 Q2 | -521 Thousand USD | -3821.43% |
| 2020 Q1 | -1.02 Million USD | -302.38% |
| 2020 Q4 | -1.37 Million USD | -187.42% |
| 2020 Q3 | -477 Thousand USD | -144.62% |
| 2020 FY | -3.06 Million USD | -1901.96% |
| 2020 Q2 | -195 Thousand USD | 80.88% |
| 2019 Q1 | 41 Thousand USD | 154.67% |
| 2019 Q4 | 504 Thousand USD | 301.6% |
| 2019 FY | -153 Thousand USD | -1192.86% |
| 2019 Q3 | -250 Thousand USD | 44.32% |
| 2019 Q2 | -449 Thousand USD | -1195.12% |
| 2018 Q3 | -32 Thousand USD | -129.09% |
| 2018 Q1 | 11 Thousand USD | -96.23% |
| 2018 FY | 14 Thousand USD | -98.9% |
| 2018 Q4 | -75 Thousand USD | -134.38% |
| 2018 Q2 | 110 Thousand USD | 900.0% |
| 2017 Q3 | 337 Thousand USD | -39.28% |
| 2017 Q1 | 94 Thousand USD | 104.99% |
| 2017 FY | 1.27 Million USD | 142.04% |
| 2017 Q2 | 555 Thousand USD | 490.43% |
| 2017 Q4 | 292 Thousand USD | -13.35% |
| 2016 FY | -3.04 Million USD | -434.43% |
| 2016 Q2 | -262 Thousand USD | 50.47% |
| 2016 Q1 | -529 Thousand USD | 33.46% |
| 2016 Q3 | -365 Thousand USD | -39.31% |
| 2016 Q4 | -1.88 Million USD | -416.16% |
| 2015 Q1 | 142 Thousand USD | 129.04% |
| 2015 Q2 | 28 Thousand USD | -80.28% |
| 2015 Q3 | 1.53 Million USD | 5378.57% |
| 2015 Q4 | -795 Thousand USD | -151.83% |
| 2015 FY | 909 Thousand USD | 172.16% |
| 2014 FY | 334 Thousand USD | -59.76% |
| 2014 Q4 | -489 Thousand USD | -291.02% |
| 2014 Q3 | 256 Thousand USD | 143.81% |
| 2014 Q2 | 105 Thousand USD | -77.27% |
| 2014 Q1 | 462 Thousand USD | 371.43% |
| 2013 FY | 830 Thousand USD | 114.6% |
| 2013 Q4 | 98 Thousand USD | -77.63% |
| 2013 Q3 | 438 Thousand USD | 4966.67% |
| 2013 Q2 | -9000.00 USD | -102.98% |
| 2013 Q1 | 302 Thousand USD | 114.12% |
| 2012 Q1 | -1.3 Million USD | -240.84% |
| 2012 Q3 | -540 Thousand USD | 68.33% |
| 2012 FY | -5.68 Million USD | -541.8% |
| 2012 Q2 | -1.7 Million USD | -30.95% |
| 2012 Q4 | -2.13 Million USD | -296.11% |
| 2011 Q2 | 650 Thousand USD | 20.82% |
| 2011 Q4 | -382 Thousand USD | -179.42% |
| 2011 Q1 | 538 Thousand USD | 2021.43% |
| 2011 FY | 1.28 Million USD | 164.45% |
| 2011 Q3 | 481 Thousand USD | -26.0% |
| 2010 Q1 | -1.24 Million USD | -387.11% |
| 2010 Q2 | -1.28 Million USD | -2.73% |
| 2010 Q3 | 558 Thousand USD | 143.56% |
| 2010 FY | -1.99 Million USD | 56.59% |
| 2010 Q4 | -28 Thousand USD | -105.02% |
| 2009 Q4 | -256 Thousand USD | 55.17% |
| 2009 FY | -4.6 Million USD | -264.64% |
| 2009 Q1 | -1.57 Million USD | -121.07% |
| 2009 Q2 | -2.2 Million USD | -39.77% |
| 2009 Q3 | -571 Thousand USD | 74.05% |
| 2008 Q3 | 1.17 Million USD | 960.36% |
| 2008 Q4 | -712 Thousand USD | -160.49% |
| 2008 Q1 | 286 Thousand USD | 244.58% |
| 2008 Q2 | 111 Thousand USD | -61.19% |
| 2008 FY | 2.79 Million USD | 16.9% |
| 2007 Q2 | 453 Thousand USD | -37.86% |
| 2007 Q4 | 83 Thousand USD | -92.62% |
| 2007 Q3 | 1.12 Million USD | 148.34% |
| 2007 FY | 2.39 Million USD | 169.83% |
| 2007 Q1 | 729 Thousand USD | 152.09% |
| 2006 Q1 | -913 Thousand USD | -328.82% |
| 2006 Q2 | 1.16 Million USD | 227.82% |
| 2006 Q3 | -2.27 Million USD | -295.29% |
| 2006 Q4 | -1.39 Million USD | 38.59% |
| 2006 FY | -3.42 Million USD | -371.63% |
| 2005 Q1 | 905 Thousand USD | 352.09% |
| 2005 Q2 | -976 Thousand USD | -207.85% |
| 2005 Q3 | 932 Thousand USD | 195.49% |
| 2005 Q4 | 399 Thousand USD | -57.19% |
| 2005 FY | 1.26 Million USD | 396.06% |
| 2004 Q3 | 1.23 Million USD | 328.84% |
| 2004 Q1 | -84 Thousand USD | 77.66% |
| 2004 FY | 254 Thousand USD | -68.25% |
| 2004 Q4 | -359 Thousand USD | -129.0% |
| 2004 Q2 | -541 Thousand USD | -544.05% |
| 2003 Q2 | -147 Thousand USD | -131.34% |
| 2003 Q1 | 469 Thousand USD | 440.74% |
| 2003 FY | 800 Thousand USD | -50.82% |
| 2003 Q4 | -376 Thousand USD | -144.03% |
| 2003 Q3 | 854 Thousand USD | 680.95% |
| 2002 Q3 | 308 Thousand USD | -61.26% |
| 2002 Q4 | 86.73 Thousand USD | -71.84% |
| 2002 FY | 1.62 Million USD | -53.39% |
| 2002 Q2 | 795 Thousand USD | 81.92% |
| 2002 Q1 | 437 Thousand USD | -52.1% |
| 2001 Q4 | 912.4 Thousand USD | -5.74% |
| 2001 FY | 3.49 Million USD | 392.74% |
| 2001 Q3 | 968 Thousand USD | -13.49% |
| 2001 Q2 | 1.11 Million USD | 127.9% |
| 2001 Q1 | 491 Thousand USD | 557.57% |
| 2000 Q4 | -107.3 Thousand USD | -21.94% |
| 2000 Q2 | -525 Thousand USD | -31.25% |
| 2000 Q1 | -400 Thousand USD | -200.0% |
| 2000 Q3 | -88 Thousand USD | 83.24% |
| 2000 FY | -1.19 Million USD | -232.48% |
| 1999 Q3 | 100 Thousand USD | -75.0% |
| 1999 Q2 | 400 Thousand USD | 0.0% |
| 1999 Q1 | - USD | 100.0% |
| 1999 FY | 900 Thousand USD | 28.57% |
| 1999 Q4 | 400 Thousand USD | 300.0% |
| 1998 Q4 | -200 Thousand USD | -166.67% |
| 1998 Q1 | 300 Thousand USD | 2900.0% |
| 1998 Q2 | 400 Thousand USD | 33.33% |
| 1998 FY | 700 Thousand USD | -36.36% |
| 1998 Q3 | 300 Thousand USD | -25.0% |
| 1997 FY | 1.1 Million USD | 0.0% |
| 1997 Q4 | 10 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aspira Women's Health Inc. | -18.85 Million USD | -332.103% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -921.669% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -692.168% |
| Standard BioTools Inc. | -76.6 Million USD | -6.345% |
| Prenetics Global Limited | -52.51 Million USD | -55.122% |
| Neuronetics, Inc. | -30.55 Million USD | -166.61% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -1774.367% |
| Castle Biosciences, Inc. | -67.97 Million USD | -19.835% |
| Psychemedics Corporation | -2.92 Million USD | -2688.771% |
| RadNet, Inc. | 98.69 Million USD | 182.535% |
| Exact Sciences Corporation | -215.01 Million USD | 62.114% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 107.425% |
| iSpecimen Inc. | -11.16 Million USD | -629.317% |
| OpGen, Inc. | -15.68 Million USD | -419.235% |
| Exagen Inc. | -22.83 Million USD | -256.702% |
| Bionano Genomics, Inc. | -215.24 Million USD | 62.155% |
| CareDx, Inc | -101.9 Million USD | 20.059% |
| Check-Cap Ltd. | -19.28 Million USD | -322.357% |
| Twist Bioscience Corporation | -220.83 Million USD | 63.112% |
| Guardant Health, Inc. | -564.72 Million USD | 85.575% |
| Biodesix, Inc. | -41.34 Million USD | -97.039% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -3040.823% |
| Precipio, Inc. | -7.62 Million USD | -969.029% |
| Natera, Inc. | -446.24 Million USD | 81.745% |
| Fulgent Genetics, Inc. | -72.69 Million USD | -12.057% |
| Sera Prognostics, Inc. | -39.82 Million USD | -104.565% |
| 23andMe Holding Co. | -321.35 Million USD | 74.651% |
| OPKO Health, Inc. | -157.02 Million USD | 48.122% |
| Personalis, Inc. | -109.93 Million USD | 25.902% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 16.329% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -643.703% |
| T2 Biosystems, Inc. | -49.66 Million USD | -64.022% |
| Neogen Corporation | 58.66 Million USD | 238.861% |
| Myriad Genetics, Inc. | -123.7 Million USD | 34.147% |
| ICON Public Limited Company | 956.15 Million USD | 108.52% |
| NeoGenomics, Inc. | -107.73 Million USD | 24.389% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -1774.367% |
| MDxHealth SA | -27.32 Million USD | -198.093% |
| Prenetics Global Limited | -52.51 Million USD | -55.122% |
| Illumina, Inc. | -1.06 Billion USD | 92.38% |
| DarioHealth Corp. | -56.18 Million USD | -44.975% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -674.281% |
| Medpace Holdings, Inc. | 336.82 Million USD | 124.185% |
| Mainz Biomed B.V. | -26.64 Million USD | -205.727% |
| Trinity Biotech plc | -27.04 Million USD | -201.202% |
| Sotera Health Company | 276.69 Million USD | 129.441% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -921.669% |